Skip to main content

Table 1 Associations of emmprin with clinical factors in endometrial cancer patients

From: Role of emmprin in endometrial cancer

   Emmprin  
   Variable Numbers mean ± SE p-value
Age (years)    0.445
<60 80 1.38 ± 0.70  
≥60 54 1.48 ± 0.84  
FIGO stage    0.009*
I-II 85 1.30 ± 0.65  
III-IV 49 1.61 ± 0.67  
Histology    0.017*
Type I (G1 + G2) 106 1.34 ± 0.69  
Type II (G3 + carcinosarcoma) 28 1.68 ± 0.54  
Depth of myometrial invasion    0.001*
<1/2 87 1.28 ± 0.66  
≥1/2 47 1.66 ± 0.63  
Cervical involvement    0.001*
Negative 105 1.32 ± 0.67  
Positive 29 1.75 ± 0.57  
Lymph node metastasis    <0.001*
Negative 116 1.34 ± 0.67  
Positive 18 1.89 ± 0.47  
LVS involvement    <0.001*
Negative 90 1.27 ± 0.67  
Positive 44 1.70 ± 0.59  
Ovarian metastasis    0.127
Negative 119 1.38 ± 0.66  
Positive 15 1.66 ± 0.72  
Peritoneal cytology    0.031*
Negative 105 1.35 ± 0.67  
Positive 29 1.65 ± 0.61  
  1. *Mann–Whitney U-test; FIGO, International Federation of Gynecology and Obstetrics; LVS, lymph vascular space.